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Abstract 
Background & aims: The ALBI grade was proposed as an objective means to 
evaluate liver function in patients with Hepatocellular Carcinoma (HCC). ALBI grade 
1 vs 2 were proposed as stratification factors within the Child Pugh (CP) A class. 
However, the original publication did not provide comparison with the sub-
classification by points (5 to 15) within the CP classification.  
Methods: We retrospectively analyzed data from patients treated with sorafenib for 
HCC from 17 centers in United Kingdom and France. Overall survival (OS) was 
analyzed with the Kaplan-Meier method and a Cox regression model. Discriminatory 
abilities of the classifications were assessed with the log likelihood ratio, Harrell’s C 
statistics and Akaike information criterion.  
Results: Data from 1,019 patients were collected, of which 905 could be assessed for 
both scores. 92% of ALBI grade 1 were CP A5 while ALBI 2 included a broad range 
of CP scores of which 44% were CP A6. Median OS was 10.2, 7.0 and 3.6 months 
for CP scores A5, A6 and >A6, respectively (P<0.001), Hazard Ratio (HR)=1.60 
(95%CI: 1.35-1.89, P<0.001) for A6 vs A5. Median OS was 10.9, 6.6 and 3.0 months 
for ALBI grade 1, 2 and 3, respectively (P<0.001), HR=1.68 (1.43-1.97, P<0.001) for 
grade 2 vs 1. Discriminatory abilities of CP and ALBI were similar in the CP A 
population, but better for CP in the overall population.  
Conclusions: Our findings support the use CP class A as an inclusion criterion, and 
ALBI as a stratification factor in trials of systemic therapy. 
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Key points: 
- This series offers a comparison of CP by points and ALBI in a large population of 
patients treated with sorafenib 
- CP A class was a better inclusion criteria than ALBI grade 1 or ALBI grade ≤2 
- ALBI grade and CP sub classification by points offered similar discriminative 
abilities when analyzed within the CP A class 
- We proposed that CP class A should be used as an inclusion criteria, and ALBI 
grade as a stratification factor in clinical trials of systemic therapy  
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Introduction 
Hepatocellular Carcinoma (HCC) is the second most common cause of cancer death  
worldwide [1]. As most cases arise in patients with chronic liver disease, the 
prognosis and treatment algorithms need to take into account both tumoral 
characteristics (such as size, number of lesions, portal vein thrombosis, extra-hepatic 
spread) and liver function [2]. A number of different composite scoring systems are 
currently used to define the extent of underlying liver dysfunction but the most widely 
is the Child-Pugh (CP) [2–5]. 
However, CP score has many limitations, including the empiric development of the 
score, and the subjectivity of some parameters including the clinical assessment of 
ascites and encephalopathy [3]. The Albumin-Bilirubin (ALBI) grade was recently 
proposed as an objective alternative to the CP classification in patients with HCC [6]. 
The ALBI grade was developed with the inclusion of variables representing liver 
functions (excluding tumoral characteristics) that were independently associated with 
survival, and was validated in large databases of patients treated with different 
treatment modalities in different countries. The score is calculated from serum 
albumin and bilirubin concentrations analyzed as continuous variables, and is then 
categorized in three grades. The calculation of the score requires a complex formula, 
but an approximation can be estimated using a nomogram, and the grade can also 
be assigned using a heat map, both provided in the original publication. As only 
albumin and bilirubin values are required, ALBI grade is entirely objective.  
ALBI grade was proposed as an alternative to the CP score, with an emphasis put on 
the ability of ALBI grade 1 vs 2 to discriminate prognosis in patients with CP score A, 
thus potentially allowing stratification in clinical trials [6]. However, a limitation of the 
original publication was the absence of comparison with the CP sub-classification by 
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points (5 to 15). Hence it was not possible to determine the extent to which ALBI 
grade 1 and 2 differed from CP 5 and 6 with respect to sub-classifying CP A grade 
patients. Understanding this comparison has important implications for the 
implementation of ALBI. Our aim here was to compare the prognostic value of ALBI 
classification with CP sub-classification by points, in patients treated with sorafenib 
for HCC. The study was compliant with the STROBE guidelines [7]. 
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Methods 
Patients: 
We retrospectively collected data from patients treated with sorafenib for advanced 
HCC from 17 centers in the United Kingdom and France. Data was acquired under 
an ethically approved protocol (REC reference 12/LO/1088). As a retrospective audit, 
we were advised by the ethical committee that written informed consent was not 
required. The data bases were anonymized. All consecutive patients treated with 
sorafenib were entered in the databases. HCC was confirmed either by biopsy or by 
radiologic criteria [2]. Relevant authorizations were obtained from institutional and 
ethical review boards for use of the data. Data collected included age, gender, cause 
of underlying liver disease, previous treatment for HCC, presence of extrahepatic 
spread, presence of portal vein thrombosis, performance status, alpha-fetoprotein, 
prothrombin time or International Normalized Ratio (INR), albumin, bilirubin, ascites 
and encephalopathy (as coded by centers for the CP classification), Barcelona Clinic 
for Liver Cancer (BCLC) classification and CP score as provided by centers. All data 
were obtained at the initiation of sorafenib. 
 
Calculation of the liver functions scores: 
In an effort to control for bias coming from miscoding, the CP score was then 
calculated from raw data, according to the original publication and adaptation for 
normalization of units used (Table 1) [3,5,8,9]. When both INR and prothrombin time 
were provided, INR was preferred. If the patient was recorded as receiving 
anticoagulation treatment, the CP coagulation score was assumed to be 1. The ALBI 
score was calculated using the formula: ALBI score = (log10 bilirubin x 0.66) + 
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(albumin x - 0.085), and grades were attributed as follows: grade 1 if score ≤ -2.60; 
grade 2 if score > -2.60 but ≤-1.39; grade 3 if score >-1.39 [6]. 
 
Statistical analysis: 
Statistical analyses and graphs were performed on R statistical software version 
3.1.1 (2014-07-10). Analyses were conducted on all patients, then on patients with a 
calculated CP class A only. Patients’ characteristics were described by medians and 
range, and frequencies. Overall survival (OS) was calculated from the start of 
treatment with sorafenib to death, survival curves were estimated with the Kaplan-
Meier approach, and compared with Log-Rank tests. A p value < 0.05 was 
considered as statistically significant for all analyses. 
Reliability of CP score and ALBI grade was evaluated using contingency tables, raw 
concordance rates and quadratic weighted kappa coefficients with adjusted bootstrap 
percentile confidence interval.  
The performance of a prognostic system has been shown to be related to 
homogeneity (small differences in survival among patients in the same class within 
each system) and discriminatory ability (greater differences in survival among 
patients in different stages within each system) [10,11].  
Harrell’s C statistics was used to measure the discriminatory ability of CP scores and 
the ALBI score. A higher Harrell’s C statistics indicates higher discriminative ability. 
The log likelihood ratio was calculated with Cox regression to determine 
homogeneity. A higher log likelihood ratio indicates higher homogeneity of survival 
between patients classified in a same class. In addition, the results of Cox regression 
were expressed using the Akaike information criterion (AIC), which shows how the 
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model, and so how the explanatory variable (the staging system) is informative, 
meaning that the staging system explains by itself most of the difference in prognosis 
between patients. The lower the AIC, the lower the model loses information and the 
better the goodness of fit. We calculated the relative likelihood of ALBI vs CP using 
the formula: exp((AICCP/AICALBI)/2). The relative likelihood represents the probability 
that ALBI minimizes information as effectively as CP, and could thus be interpreted 
as a p value for the comparison of both AIC. For these analyses, the classifications 
were compared as ALBI grade 1 vs 2 vs 3 and CP A5 vs A6 vs >A6 for the whole 
population, and ALBI grade 1 vs 2 and CP A5 vs A6 for the CP A population. We 
grouped together all patients with >A6 score due to low numbers in each class, usual 
grouping of CP B patients in clinical studies, and similar survival of patients with CP 
B7 and >B7. 
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Results 
Patient characteristics and Child-Pugh scoring 
From February 2003 to August 2014, 1019 patients were treated with sorafenib for 
HCC. The characteristics of the cohort are presented in Table 2. Median follow-up 
was 14.3 months, and 843 patients (82.7%) died. 
All data for calculation of CP scores were available in 905 patients (88.8%). As 
shown in the flow-chart diagram (Figure 1), most missing values were coagulation, 
followed by encephalopathy and albumin. As presented in the Supplementary Table, 
there were discrepancies between CP score calculated from raw data using our CP 
classification and CP score provided by centers. Overall, results were discrepant in 
109 out of 904 patients (12.1%). However, the overall concordance stayed excellent, 
with a kappa of 0.90 (95% Confidence Interval (CI): 0.87-0.92). The cause of 
misclassification could be determined when the CP score provided was 5 but our 
calculation based on raw data was >5: in the 42 patients with a calculated CP of 6, 
the abnormal value was albumin in 39 and bilirubin in 3 cases; in the 4 patients with 
CP calculated at 7, abnormal values were albumin and bilirubin both misclassified in 
3, and bilirubin alone misclassified in 1. Using the CP given by our calculations, 
abnormal values leading to CP A6 score (n=264) were albumin in 195 (73.9%), 
ascites in 36 (13.6%), bilirubin in 28 (10.6%), encephalopathy in 4 (1.5%) and 
coagulation in 1 (0.4%). Values leading to CP B7 (n=101) involved albumin in 81 
(80.2%), bilirubin in 49 (48.5%), ascites in 31 (30.7%), coagulation in 5 (5.0%) and 
encephalopathy in 3 (3.0%). Thus, in this population, albumin was the main driver of 
CP A5 vs A6 vs B7 classification, followed by bilirubin and ascites. 
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Child-Pugh and ALBI grade comparison 
ALBI grade could be calculated for 962 patients (94.4%), including all patients with 
allocated CP score. Median ALBI score was -2.36 (range: -4.39/-0.35)). Overall, 327 
patients (34.0%) were ALBI grade 1, 574 (59.7%) were grade 2 and 61 (6.3%) were 
grade 3. Comparison between ALBI grade and CP scores are reported in Table 3 for 
the 905 patients with both scores. While 91.7% of ALBI grade 1 patients were 
classified as CP A5, ALBI grade 2 comprised patients with CP A6 in 44.3%, CP A5 in 
33.3%, and CP >A6 in 22.4%. ALBI grade 3 patients were all classified as CP >A6. 
Two patients with ALBI grade 1 were classified as CP B7, and 6 patients with ALBI 
grade 2 were classified as CP B9; such discrepancies were always explained by 3 
points given to ascites, except for one ALBI grade 2 case with 2 points given to 
ascites and 2 points to coagulation. 
CP scores were significantly associated with OS (log-rank p<0.001), with median OS 
of 10.2 months (95%CI: 8.6-11.7) in CP A5 (n=458), 7.0 (95%CI: 6.1-7.9) in CP A6 
(n=264, p<0.001 vs CP A5), 3.6 (95%CI: 3.1-4.2) in CP >A6 (n=183, p<0.001 vs CP 
A6) (Figure 2A). If separated from patients with CP >B7, CP B7 patients (n=101) still 
had a dismal prognosis, with median OS of 3.9 months (95%CI: 2.7-5.1, p=0.009 vs 
CP A6, p=0.57 vs CP B8). The Hazard Ratio (HR) for OS between A6 vs A5 was 
1.60 (95%CI: 1.35-1.89, p<0.001), and between >A6 vs A5 was 2.49 (95%CI: 2.07-
3.00, p<0.001).  
ALBI grades were also significantly associated with OS (log-rank p<0.001), with 
median OS of 10.9 months (95%CI: 9.2-12.6) for ALBI grade 1 (n=302), 6.6 (95%CI: 
5.9-7.3) for ALBI grade 2 (n=544, p<0.001 vs ALBI grade 1), and 3.0 (95%CI: 2.1-
3.8) for ALBI grade 3 (n=59, p<0.001 vs ALBI grade 3) (Figure 2B). The HR between 
ALBI grade 2 vs grade 1 was 1.68 (95%CI: 1.43-1.97, p<0.001), and between ALBI 
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grade 3 vs grade 1 was 3.36 (95%CI: 2.48-4.56, p<0.001). Focusing on the CP class 
A population (n=722), median OS was 8.8 months (95%CI: 8.0-9.6), and when the 
group was split according to ALBI grade was 10.9 months (95%CI: 9.2-12.7) for ALBI 
grade 1 and 7.5 (95%CI: 6.7-8.3, p<0.001) for ALBI grade 2, with a HR=1.54 (95%CI: 
1.30-1.82, p<0.001).  
In patients classified as ALBI grade 1 (n=302), CP A5 patients (n=277) had 
significantly better survival than CP A6 patients (n=23), with respective median OS of 
11.6 (95%CI: 9.9-13.3) and 7.9 months (95%CI: 4.4-11.3) (p=0.008, Figure 3A). In 
patients classified as ALBI grade 2 (n=544), median OS were 8.6 months (95%CI: 
6.9-10.3) in CP A5 (n=181), 6.9 (95%CI: 6.0-7.9, p=0.016 vs CP A5) in CP A6 
(n=241) and 3.9 (95%CI: 3.2-4.6, p=0.002 vs CP A6) in patients with CP >A6 (n=122) 
(Figure 3B). 
In patients classified as CP A5 (n=458), ALBI grade 1 patients (n=277) had 
significantly better survival than ALBI grade 2 patients (n=181), with respective 
median OS of 11.6 (95%CI: 9.9-13.3) and 8.6 months (95%CI: 6.9-10.3) (p=0.003, 
Figure 3C). However, in patients classified as CP A6 (n=264), there was no 
significant difference between patients classified as ALBI grade 1 (n=23) and grade 2 
(n=241), with respective median OS of 7.9 (95%CI: 4.4-11.3) and 6.9 months 
(95%CI: 6.0-7.9) (p=0.96, Figure 3D). In patients with CP >A6 (n=183), there was no 
difference between ALBI grade 2 (n=122) and grade 3 (n=59), with respective 
median OS of 3.9 (95%CI: 3.2-4.6) and 3.0 months (95%CI: 2.1-3.8) (p=0.17, Figure 
3E). 
Combining both classifications might offer a broader range of prognosis (Figure 3F 
and Table 4), classifying patients with progressively worse prognosis as CP A5-ALBI 
1, CP A5-ALBI 2, CP A6-ALBI 1, CP A6-ALBI 2, CP >A6-ALBI 2 and CP >A6-ALBI 3. 
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However, numbers in certain subgroups (especially CP A6-ALBI 1) are too low to 
draw definitive conclusions. 
Results regarding the discriminative abilities of both scoring systems are reported on 
Table 5. CP was associated with less information loss than ALBI in the overall 
population as evidenced by a lower AIC with a relative likelihood <0.001. However, 
this was not the case when only the CP class A population was considered. 
Moreover, discriminative abilities of CP and ALBI were very similar as evidenced by 
similar Harrell’s C statistics, either in the overall population or the CP class A 
population, showing that both staging systems are equally able to accurately 
differentiate the prognosis of patients. Likewise, homogeneity of classes appeared 
different in the overall population, as illustrated by higher likelihood ratio score for CP 
representing better homogeneity of the CP system in this population, meaning that a 
same ALBI grade might group together patients with different prognosis. However, 
homogeneity was similar between both scoring systems when focusing in the CP 
class A population. Similar results were found if CP scores provided by centers were 
used, rather than CP scores calculated. Hence, the CP score might be more 
informative than ALBI in the overall population, but the CP score and the ALBI grade 
showed very similar prognostic abilities in the CP class A population.   
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Discussion 
In this large retrospective series of European patients treated with sorafenib for 
advanced HCC, we found that ALBI grade and CP sub-classification by points 
provide similar prognostic information when focusing on CP A population. The 
majority of patients classified as ALBI grade 1 were also classified as CP A5, while 
the patients classified as ALBI grade 2 showed a broader range of classification 
within CP scores, including many patients with CP B. To our knowledge, this is the 
first multicenter study comparing ALBI and CP sub-classification by points in a large 
number of European patients, and our findings are supported by those of two 
recently published  studies from Asia [12,13]. Moreover, two recent studies 
originating from the same consortium showed that the incorporation of ALBI into the 
BCLC or Japan Integrated Staging (JIS) classification could add information over CP 
[14,15]. 
The ALBI grade was developed as an evidence-based scoring system specifically for 
assessing liver function in patient with HCC and uses only albumin and bilirubin 
which are independently associated with OS [6]. The formula derived from the model 
avoids subjectively chosen thresholds so that albumin and bilirubin are analyzed as 
continuous variable using international units rather than categorical variables. 
However, thresholds were introduced to allow the allocation of grade based on risk. 
Using a Japanese training set, the grades were defined to classify the 25% with the 
lowest risk of death as grade 1, those 10% with highest risk of death as grade 3 and 
those in between as grade 2. The model was then validated in independent 
international cohorts using different treatment modalities. The use of a formula might 
be judged cumbersome, but a nomogram and a heat map are provided, thus allowing 
easier use in a clinical setting.  
16 
 
Conversely, and as already discussed in previous publications [3,6], the CP scoring 
system has several limitations for use in patients with HCC. First, it was developed 
using an empiric approach rather than evidence-based and was intended to be used 
to define the operative risk in cirrhotic patients with esophageal varices. Therefore it 
is not strictly applicable to non-cirrhotic patients with HCC. Second, two of the five 
factors that contribute to the CP score -clinical ascites and encephalopathy- are 
subjective and prone to error. Finally, the score gives similar weighting to parameters 
which may not be of similar prognostic importance. Despite these limitations, CP 
score consistently emerges as a significant prognostic factor in clinical series 
evaluating outcomes from therapeutic interventions. Given its widespread use, most 
publications do not define the CP [16] yet we found surprisingly significant 
discrepancies in scoring, illustrated by a 12% discordance between our score based 
on the raw data and the score provided by the participating centers. At least two 
explanations could be found for such high discrepancies. First, there is surprisingly 
no international consensus about CP scoring system, as illustrated by different 
thresholds proposed for bilirubin (34, 35, 50 or 51 µmol/L) [5,9,17–21]. Second, 
miscoding errors at the thresholds values are frequent, as presented by 39% of the 
patients with errors in our cohorts. Using only two variables, ALBI might be less 
prone to such coding-related errors. However, despite these miscoding of CP scores, 
the concordance between provided and calculated CP scores remained excellent 
with a kappa at 0.90, which is superior than kappa obtained for inter-observer 
variability judged acceptable in radiological evaluation, in the range of 0.50 to 0.60 
[22,23].  
The respective roles of ALBI and CP in clinical practice and research need to be 
considered in view of our results. Broadly, these classifications have a potential role 
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in patient selection and stratification, and to date, the majority of clinical trials in 
advanced HCC have included CP A disease as a key inclusion criteria. 
Our results suggest that ALBI grade should not be used instead of CP as an 
inclusion criteria for clinical trials. First, the ALBI grade 2 has an intermediate 
prognosis (median OS of 6.6 months), but seems to encompass patients with quite 
different prognosis, as shown by higher loss of information and lower homogeneity 
for ALBI as compared with CP in the overall population, and illustrated by a median 
of 8.9 months for ALBI grade 2 – CP A5 vs 3.9 months for ALBI grade 2 – CP >A6. 
This is probably related to the chosen design of ALBI grade 2, comprising patients 
between 25% and 90%-risk of death. Moreover, one might advocate to select only 
ALBI grade 1 CP A5 patients, as this population appears to have the best prognosis. 
However, that could exclude a significant number of patients who might otherwise 
benefit, as was demonstrated in the SHARP trail in which a survival advantage was 
demonstrated in both CP A5 and A6 patients. Second, excluding only patients with 
ALBI grade 3 would probably be less efficient than excluding patients with CP class 
B, as ALBI grade 2 also included 22% of patients classified as CP class B, 
associated with a worse prognosis with a median OS of only 3.9 months. Another 
area of debate is the appropriate evaluation of CP class B patients. This criterion is 
frequently used for exclusion from clinical trials. Some authors advocate similar 
treatment strategies for CP B7 patients as for CP A patients, when ascites is absent 
[24]. However, in our cohort, we did not find any statistically or clinically significant 
difference in OS between patients classified as CP B7 vs CP >B7. The role of 
sorafenib in HCC patients with CP B cirrhosis is under evaluation in 2 ongoing 
randomized controlled trials (PRODIGE 21 and BOOST trials) [25,26]. 
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Conversely, the comparison of both scores when restricted to CP class A patients 
showed that taken as a whole, ALBI grade 1 vs grade 2 was able to provide similar 
information as CP A5 vs A6, with the use of only 2 objective parameters rather than 5 
parameters, some of them subjective, which suggests that ALBI might be preferred 
as a stratification factor.  
Limitations of our study comprise its retrospective nature, and the discrepancies 
between calculated and provided CP scores. Moreover, this study is limited to 
European centers, and patients treated with sorafenib, and results should be 
confirmed in other contexts. 
In conclusion, our findings support the continued use of CP class A as an inclusion 
criteria, but ALBI grade 1 vs 2 as a stratification factor for clinical trials of systemic 
therapy. Prospective studies will help to define further the relative benefits of ALBI 
and CP in different therapeutic contexts and inform clinical guidelines. 
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Table 1: Scoring used for the Child-Pugh classification (3, 5, 8) 
 1 point 2 points 3 points 
Albumin > 35 g/L 35-28 g/L < 28 g/L 
Bilirubin < 34 mcmol/L 34-51 mcmol/L > 51 mcmol/L 
Coagulation: 
-INR 
-Prothrombin 
Time, as a 
percentage relative 
to control 
 
< 1.7 
> 50% 
 
1.7-2.3 
40-50% 
 
> 2.3 
< 40% 
Ascites None Medically 
controlled 
Refractory 
Encephalopathy 
[8] 
None Grade 1 or 2 (or 
medically 
controlled) 
Grade 3 or 4 (or 
refractory) 
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Table 2: Characteristics of the cohort 
Age (n=1019) median (range) 67 (17-89) 
Gender (n=945), male / female 810 (85.7%) / 135 (14.3%) 
Excessive alcohol consumption (n=921) 375 (40.7%) 
Hepatitis B Virus (n=921) 81 (8.8%) 
Hepatitis C Virus (n=921) 164 (17.8%) 
Non-Alcoholic Steato-Hepatitis (n=921) 228 (24.8%) 
No identified cause (n=921) 258 (28.0%) 
Albumin, g/L (n=967), median (range) 37 (17-61) 
Bilirubin, mcmol/L (n=989), median 
(range) 
15 (3-436) 
Previous treatment for HCC (n=857) 495 (57.8%) 
Extra-Hepatic Spread (n=910) 338 (37.1%) 
Portal Vein Thrombosis (n=997) 375 (37.6%) 
Alpha-Feto Protein, ng/mL (n=978), 
median (range) 
128 (0-849,553) 
Performance status (n=902): 0/1/2/3 389 (43.1%) / 399 (44.2%) / 109 
(12.1%) / 5 (0.6%) 
BCLC stage (n=910): A/B/C/D 11 (1.2%) / 178 (19.6%) / 711 (78.1%) / 
10 (1.1%) 
BCLC: Barcelona Clinic for Liver Cancer; CP: Child-Pugh 
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Table 3: Correspondences between calculated Child-Pugh scores and ALBI grades 
(n=905): 
 CP A5 CP A6 CP B7 CP B8 CP B9 CP C10 CP C11 
ALBI 
grade 1 
277 23 2 0 0 0 0 
ALBI 
grade 2 
181 241 87 29 6 0 0 
ALBI 
grade 3 
0 0 12 22 12 11 2 
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Table 4: Median overall survival according to both Child-Pugh and ALBI 
classifications 
Class n median OS (95%CI) 
CP5-ALBI1 277 11.6 (9.8-13.9) 
CP5-ALBI2 181 8.6 (7.4-10.6) 
CP6-ALBI1 23 7.9 (5.8-NA) 
CP6-ALBI2 241 6.9 (6.1-7.7) 
CP>6-ALBI2 122 3.9 (3.3-5.4) 
CP>6-ALBI3 59 3.0 (2.1-4.0) 
CP: Child-Pugh; OS: Overall Survival; NA: Not assessable  
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Table 5: Discriminative abilities of Child-Pugh and ALBI scoring systems. A higher 
Harrell’s C statistics indicates higher discriminative ability (patients of different risk 
groups have higher difference in survival). A higher log likelihood ratio indicates 
higher homogeneity (similar survival between patients classified in a same class). A 
lower Akaike information criterion indicates lower loss of information (the 
classification explaining most of the difference in prognosis between patients). The 
relative likelihood calculated represents the probability that ALBI minimizes 
information loss as effectively as CP. 
 All patients (n=905) CP A patients (n=722) 
 CP ALBI CP ALBI 
Harrell’s C statistic 0.61 0.60 0.56 0.57 
Log likelihood ratio 90.7 68.3 29.0 26.3 
AIC 8876 8898 6649 6652 
Relative likelihood of ALBI 
equivalence of AIC 
comparatively to CP 
<0.001 0.22 
AIC: Akaike Information Criterion; CP: Child-Pugh 
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Figures legends: 
Fig. 1: Flow-chart diagram of patients included in the study. 
Fig. 2: Overall survival according to (A) Child-Pugh scores and (B) ALBI grade. 
Fig. 3: Overall Survival according to Child-Pugh score (A and B) in patients classified 
as (A) ALBI grade 1 and (B) ALBI grade 2, and according to ALBI grade (C, D and E) 
in patients classified as (C) Child-Pugh A5, (D) Child-Pugh A6 and (E) Child-Pugh B7 
or more. 
 
